Grove Biopharma to Showcase Breakthrough Bionic Biologics™ at ACS Fall 2025 Symposium on Materials Biology Grove Biopharma, a private biotechnology company advancing an innovative therapeutic approach it calls Bionic Biologics™, announced that it will present updates on its research at…
Omeros Corporation Reports Second Quarter 2025 Financial Results, Advances Narsoplimab Regulatory Reviews, and Strengthens Balance Sheet Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company dedicated to developing novel therapeutics for serious diseases, today announced its financial results for the second quarter…
Cybin Announces Major Clinical and Regulatory Milestones Alongside First Quarter Fiscal Year 2026 Financial Results Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN), a clinical-stage breakthrough neuropsychiatry company focused on transforming mental health care through the development of next-generation psychedelic-based…
Alto Neuroscience Appoints Raymond Sanchez, M.D., to Board of Directors, Strengthening Leadership as Company Advances Late-Stage Precision Psychiatry Pipeline Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company pioneering the development of novel precision medicines for neuropsychiatric disorders, today…
Pilatus Biosciences Launches Clinical Trial Collaboration with Roche to Advance First-in-Human Evaluation of PLT012 in Liver Cancer Pilatus Biosciences, Inc., a biotechnology company focused on developing innovative metabolic checkpoint immunotherapies for difficult-to-treat liver and gastrointestinal cancers, announced today a new…
Newron Pharmaceuticals Launches Pivotal Phase III ENIGMA-TRS Program, Randomizing First Patients to Evaluate Evenamide as an Add-On Therapy in Treatment-Resistant Schizophrenia Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical company specializing in therapies for diseases affecting the central and…
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results, Advances Tecarfarin Clinical Development, and Strengthens Strategic Position in Anticoagulation Market Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company dedicated to developing next-generation anticoagulation therapies that address significant unmet needs in patient…
C2N Diagnostics Accelerates Global Expansion with Six New International Partnerships to Broaden Access to Alzheimer’s Blood Testing C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company committed to its mission of delivering Clarity Through Innovation®, has taken a significant step toward…
Palleon Pharmaceuticals Initiates Phase 2 Clinical Trial of E-602 (HLX79) in Combination with HANLIKANG (Rituximab Biosimilar) for Patients with Active Glomerulonephritis Palleon Pharmaceuticals, a biotechnology company at the forefront of glyco-immunology drug development for autoimmune diseases and cancer, has announced…
U.S. Hospitals Achieve Significant Gains in Surgical Patient Outcomes Since 2019, AHA and Vizient Report Shows In a compelling new report released jointly by the American Hospital Association (AHA) and Vizient®, researchers have found that outcomes for hospitalized surgical patients…
United Therapeutics Launches $1 Billion Accelerated Share Repurchase Initiative, Underscoring Confidence in Long-Term Growth and Shareholder Value In a bold affirmation of its robust financial health, strategic vision, and shareholder-centric philosophy, United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation…
Arrowhead’s Subsidiary Visirna Transfers Greater China Rights to Plozasiran to Sanofi in Strategic $395 Million Deal Amid Regulatory Milestone in Hypertriglyceridemia In a move poised to reshape the therapeutic landscape for patients with severe lipid disorders in China, Arrowhead Pharmaceuticals,…